National Shortage of Isoniazid (INH) 300 mg Tablets

The Department of Public Health and Social Services(DPHSS) would like to inform the community that there is currently a national shortage of the anti-tuberculosis medication Isoniazid (INH) 300 mg tablets.

INH is one of the most important 1st line drugs used to treat active tuberculosis (TB) and inactive TB/ Latent TB Infection (LTBI). Because of the shortage of INH, routine preventive/prophylactic treatment for inactive /Latent TB will be suspended. The limited supply of INH will be reserved for treatment of patients with active TB.

The DPHSS, TB Control Program will continue to issue clients the Certificate of TB Evaluation/Clearance for school/work, provided theyhave no signs/symptoms suggestive of active TB and have normal chest-rays. Once the DPHSS, TB Control Program is assured of a consistent supply of INH, the staff will recall the patients with Latent TB who need to receive INH preventive treatment.

The Centers for Disease Control and Prevention and the Federal Drug Agency are collaborating to identify solutions to ensure a continuous supplyof INH. For more information, contact Cecilia T.T. Arciaga,TB Program Manager at 735-3602 or Josie T. O’Mallan, Administrator, Bureau of Communicable Disease Control at 735-7142/7135.


Skip to content